EZH2 and acute myeloid leukemia: Consistently, EZH2 mutations have been associated with poor overall survival in patients with chronic myeloid neoplasms [30,54,66] and poor response to hypomethylating agents [67] but not with a higher risk of AML-MRC transformation.